In the study, a once-daily, single-tablet combination of bictegravir and lenacapavir was as effective as Gilead's existing ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

"Gilead’s HIV ART combo deemed non-inferior in second Phase III trial" was originally created and published by Clinical ...

Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...

Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...

Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google. It is the first work ...

By Dana PiccoliNEWS IS OUT The Choose U World AIDS Day panel brought together three longtime advocates living with HIV to ...

Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue ...

An updated Canadian guideline on HIV prevention addresses the expanding range of medications available to reduce the risk of ...

Over time, clonal expansion leads to an increase in the frequency of infected cells in a patient. The proviruses in daughter ...